{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:19:37Z","timestamp":1767838777701,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.05.054","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T04:39:00Z","timestamp":1467002340000},"page":"3810-3816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months"],"prefix":"10.1016","volume":"34","author":[{"given":"Sven-Arne","family":"Silfverdal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Icardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl A.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco F.","family":"Pagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Frank","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy","family":"Ziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.05.054_b0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.05.054_b0010","article-title":"Combination vaccine use and vaccination quality in a managed care population","volume":"13","author":"Happe","year":"2007","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.vaccine.2016.05.054_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/INF.0b013e318187d047","article-title":"Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population","volume":"28","author":"Happe","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.05.054_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","article-title":"The use of combination vaccines has improved timeliness of vaccination in children","volume":"25","author":"Kalies","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.05.054_b0025","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhoodcombination vaccines: from beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2016.05.054_b0030","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1097\/INF.0b013e318212eb80","article-title":"Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants","volume":"30","author":"Tregnaghi","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2016.05.054_b0035","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.054_b0040","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2012.07.040","article-title":"A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children","volume":"30","author":"Aquino","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.054_b0045","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/INF.0b013e318258400d","article-title":"Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America","volume":"31","author":"Macias","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.05.054_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2016.05.054_b0055","unstructured":"ECDC annual epidemiological report. Vaccine-preventable diseases \u2013 invasive bacterial diseases; 2014. <http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/AER-VPD-IBD-2014.pdf>."},{"key":"10.1016\/j.vaccine.2016.05.054_b0060","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/CVI.00414-13","volume":"20","author":"Vesikari","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.05.054_b0065","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1542\/peds.108.6.e115","article-title":"Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine","volume":"108","author":"Taranger","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.05.054_b0070","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2015.06.030","article-title":"Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalentvaccines. A time and motion study","volume":"33","author":"De Coster","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T07:09:41Z","timestamp":1568099381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16303802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":14,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16303802"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}